Journal: Frontiers in Immunology

Article Title: Neutrophil Extracellular Traps in Dengue Are Mainly Generated NOX-Independently

doi: 10.3389/fimmu.2021.629167

Figure Lengend Snippet: Platelets stimulate NOX-independent NET formation in a DENV NS1-dependent manner. Polymorphonuclear neutrophils (PMNs) of healthy volunteers were co-incubated with autologous platelets in the presence or absence of 10 µg/mL DENV2 NS1 or 156μM platelet agonist TRAP-6. Experiments were performed in triplicate with 2 donors for each condition. Depicted are the relative values to medium (unstimulated samples) for (A) Total NETs and (B) NOX-independent NETs. (C) Heat-inactivated DENV2 does not induce NET formation. PMNs isolated from three healthy donors were incubated with 0.5x10 7 TCID/mL heat-inactivated DENV2 or medium control (mock) in the presence or absence of autologus washed platelets (Plt). Depicted is the total NET formation (ng/mL). Data are presented as mean with standard error mean (SEM) and analyzed using repeated measure a one-way ANOVA and Bonferroni’s multiple comparisons test; * p < 0.05, **p < 0.01 . TCID, Tissue culture infectious dose.

Article Snippet: After 1h, cells were washed with pre-warmed PBS and co-cultured with or without washed platelets (ratio 1 PMN vs . 50 platelets) in the presence of the following stimuli: 10µg/mL Dengue virus-2 non-structural protein-1 (DENV2 NS1, strain Thailand/16681/84; Native Antigen, Oxford, UK) or 156 µM Thrombin Receptor Activator Peptide 6 (TRAP-6) (Sigma-Aldrich, Zwijndrecht, The Netherlands) for 3 hours at 37°C.

Techniques: Incubation, Isolation

Journal: Tropical Medicine and Infectious Disease

Article Title: A Case Report of Secondary Syphilis Co-Infected with Measles: A Diagnostic Dilemma with Fever and Rash

doi: 10.3390/tropicalmed7050070

Figure Lengend Snippet: Laboratory parameters investigated during hospitalization.

Article Snippet: These included measles and rubella IgM and IgG by enzyme-linked immunoassay (ELISA) (Euroimmun, Lubeck, Germany), dengue non-structural protein 1 (NS1) antigen (Biosynex, Swiss S.A, Fribourg, Switzerland), hepatitis B surface (HBs) antigen and anti-hepatitis HBs antibody by electrochemiluminescence immunoassay or ECLIA (Roche, Mannheim, Germany), anti-HCV antibody (hepatitis C virus) (Humasis, Gyeonggi-do, Korea), HIV antibody/antigen by ECLIA (Roche, Mannheim, Germany), plasma rapid regain or RPR (Human, Weisbaden, Germany), and T. pallidum hemagglutination or TPHA (Rapid Labs, Colchester, UK).

Techniques:

Journal: NPJ Vaccines

Article Title: An optimized purified inactivated Zika vaccine provides sustained immunogenicity and protection in cynomolgus macaques

doi: 10.1038/s41541-020-0167-8

Figure Lengend Snippet: a ZIKV Env-specific IgG ELISA titers, b ZIKV-specific microneutralization (MN 50 ) titers, and c NS1-specific IgG ELISA titers following IM vaccination of six cynomolgus macaques with each dose: 100 AU, 200 AU, or 400 AU of ZPIV-SP or 200 AU of ZPIV on day 0 and day 28 (ANOVA * P -value < 0.05; *** P -value < 0.001). Dotted lines: limit of quantification. Arrows: vaccination on D0 and D28.

Article Snippet: Envelope- and NS1-specific IgGs were assessed by ELISA in 96-well plates coated with recombinant E protein (Meridian Life Science Inc., Memphis, USA) or recombinant non-structural protein 1 (NS1) protein (Native Antigen Company, Oxford, UK) in carbonate buffer, pH 9.6.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: NPJ Vaccines

Article Title: An optimized purified inactivated Zika vaccine provides sustained immunogenicity and protection in cynomolgus macaques

doi: 10.1038/s41541-020-0167-8

Figure Lengend Snippet: a Env-specific memory B-cell ELISpot results, b NS1-specific memory B-cell ELISpot results at baseline, day 90 and day 164 following IM vaccination of cynomolgus macaques with 100, 200, or 400 AU of ZPIV-SP or 200 AU of ZPIV on day 0 and day 28. Bar = Geometric mean. (ANOVA *** P -value < 0.001). Dotted line = responder cutoff.

Article Snippet: Envelope- and NS1-specific IgGs were assessed by ELISA in 96-well plates coated with recombinant E protein (Meridian Life Science Inc., Memphis, USA) or recombinant non-structural protein 1 (NS1) protein (Native Antigen Company, Oxford, UK) in carbonate buffer, pH 9.6.

Techniques: Enzyme-linked Immunospot

Journal: NPJ Vaccines

Article Title: An optimized purified inactivated Zika vaccine provides sustained immunogenicity and protection in cynomolgus macaques

doi: 10.1038/s41541-020-0167-8

Figure Lengend Snippet: a ZIKV Env-specific IgG ELISA titers, b ZIKV-specific microneutralization (MN50) titers, and c NS1-specific IgG ELISA titers following IM vaccination of cynomolgus macaques with ZPIV-SP 100 AU on day 0, day 28, and a booster on day 176. ANOVA ** P -value < 0.01. Horizontal dotted lines = limit of quantification. Arrows = vaccination on D0, D28, and boost. Vertical dotted line = boosting dose (D176).

Article Snippet: Envelope- and NS1-specific IgGs were assessed by ELISA in 96-well plates coated with recombinant E protein (Meridian Life Science Inc., Memphis, USA) or recombinant non-structural protein 1 (NS1) protein (Native Antigen Company, Oxford, UK) in carbonate buffer, pH 9.6.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: NPJ Vaccines

Article Title: An optimized purified inactivated Zika vaccine provides sustained immunogenicity and protection in cynomolgus macaques

doi: 10.1038/s41541-020-0167-8

Figure Lengend Snippet: a Env-specific IgG ELISA titers, b ZIKV-specific microneutralization (MN 50 ) titers, and c NS1-specific IgG ELISA titers following challenge of cynomolgus macaques ( n = 6/group) on day 176 by the SC route with 10 5 PFU of PRVABC59 wt-ZIKA strain. (ANOVA ** P -value < 0.01; *** P -value < 0.001). Dotted line = limit of quantification.

Article Snippet: Envelope- and NS1-specific IgGs were assessed by ELISA in 96-well plates coated with recombinant E protein (Meridian Life Science Inc., Memphis, USA) or recombinant non-structural protein 1 (NS1) protein (Native Antigen Company, Oxford, UK) in carbonate buffer, pH 9.6.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: NPJ Vaccines

Article Title: An optimized purified inactivated Zika vaccine provides sustained immunogenicity and protection in cynomolgus macaques

doi: 10.1038/s41541-020-0167-8

Figure Lengend Snippet: a prM/Env-specific memory B-cell ELISpot responses, b NS1-specific memory B-cell ELISpot responses at baseline, day 35 and day 112 following ZIKV challenge in cynomolgus macaques with 10 5 PFU of PRVABC59 wt-ZIKA strain. Bar = Geometric mean. (ANOVA * P -value < 0.05; ** P -value < 0.01; *** P -value < 0.001). Dotted line = responder cutoff. p.c. = post-challenge.

Article Snippet: Envelope- and NS1-specific IgGs were assessed by ELISA in 96-well plates coated with recombinant E protein (Meridian Life Science Inc., Memphis, USA) or recombinant non-structural protein 1 (NS1) protein (Native Antigen Company, Oxford, UK) in carbonate buffer, pH 9.6.

Techniques: Enzyme-linked Immunospot

Journal: Eurosurveillance

Article Title: Distinction between serological responses following tick-borne encephalitis virus (TBEV) infection vs vaccination, Sweden 2017

doi: 10.2807/1560-7917.ES.2018.23.3.17-00838

Figure Lengend Snippet: Suspension multiplex immunoassay for IgM reactivity with tick-borne encephalitis whole virus vs non-structural protein 1 antigens in infected (n = 50) vs vaccinated individuals (n = 50) at 0, 120 and 390 days after first vaccination, Sweden, 2017

Article Snippet: TBEV whole virus (WV) antigen was purchased from Jena Bioscience, Jena, Germany (Cat. No. PR-BA112) and TBEV non-structural protein 1 (NS1) antigen from Native Antigen Company, Heyford Park, United Kingdom (Cat. No. TBEV-NS1–100).

Techniques: Suspension, Multiplex Assay, Virus, Infection

Journal: Eurosurveillance

Article Title: Distinction between serological responses following tick-borne encephalitis virus (TBEV) infection vs vaccination, Sweden 2017

doi: 10.2807/1560-7917.ES.2018.23.3.17-00838

Figure Lengend Snippet: Tick-borne encephalitis virus reactivity of sera from acutely infected patients (n = 50) vs vaccines (n = 50), at 0, 120 and 390 days after first vaccination, Sweden, 2017

Article Snippet: TBEV whole virus (WV) antigen was purchased from Jena Bioscience, Jena, Germany (Cat. No. PR-BA112) and TBEV non-structural protein 1 (NS1) antigen from Native Antigen Company, Heyford Park, United Kingdom (Cat. No. TBEV-NS1–100).

Techniques: Virus, Infection, Vaccines

Journal: Eurosurveillance

Article Title: Distinction between serological responses following tick-borne encephalitis virus (TBEV) infection vs vaccination, Sweden 2017

doi: 10.2807/1560-7917.ES.2018.23.3.17-00838

Figure Lengend Snippet: Suspension multiplex immunoassay for IgG reactivity with tick-borne encephalitis whole virus vs non-structural protein 1 antigens in infected (n = 50) vs vaccinated individuals (n = 50) at 0, 120 and 390 days after first vaccination, Sweden, 2017

Article Snippet: TBEV whole virus (WV) antigen was purchased from Jena Bioscience, Jena, Germany (Cat. No. PR-BA112) and TBEV non-structural protein 1 (NS1) antigen from Native Antigen Company, Heyford Park, United Kingdom (Cat. No. TBEV-NS1–100).

Techniques: Suspension, Multiplex Assay, Virus, Infection